<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Candida vulvovaginitis in adults: Treatment of acute infection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Candida vulvovaginitis in adults: Treatment of acute infection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Candida vulvovaginitis in adults: Treatment of acute infection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jack D Sobel, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert L Barbieri, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carol A Kauffman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen Eckler, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 20, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2175994530">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vulvovaginal candidiasis (VVC) is one of the most common causes of vulvovaginal itching and discharge. The disorder is characterized by inflammation in the setting of growth of
         <em>
          Candida
         </em>
         species. Treatment is indicated for the relief of symptoms and varies based on disease severity.
        </p>
        <p>
         This topic will discuss treatment of acute VVC, including both uncomplicated and complicated infections. Related topics on the general approach to patients with abnormal vaginal discharge, diagnosis of VVC, and treatment of recurrent vulvovaginal candidiasis (RVVC) are presented separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5477.html" rel="external">
          "Vaginitis in adults: Initial evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5452.html" rel="external">
          "Candida vulvovaginitis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/141182.html" rel="external">
          "Candida vulvovaginitis in adults: Recurrent infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. We encourage readers to consider the specific counseling and treatment needs of transgender and gender-diverse individuals.
        </p>
        <p class="headingAnchor" id="H1555122149">
         <span class="h1">
          WHOM TO TREAT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment is indicated for patients with both symptoms
         <strong>
          and
         </strong>
         evidence of fungal vaginal infection on microscopy or laboratory tests. Asymptomatic patients with VVC identified for other reasons (ie, Pap smear) do not require treatment; 10 to 20 percent of reproductive-age females harbor
         <em>
          Candida
         </em>
         species [
         <a href="#rid1">
          1
         </a>
         ]. Treatment approach is based on presence of uncomplicated infection (90 percent of patients) or complicated infection (10 percent of patients)  (
         <a class="graphic graphic_table graphicRef62038" href="/z/d/graphic/62038.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3240030900">
         <span class="h1">
          UNCOMPLICATED INFECTION
         </span>
        </p>
        <p class="headingAnchor" id="H905489894">
         <span class="h2">
          Criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Criteria for uncomplicated infection include
         <strong>
          all
         </strong>
         of the following  (
         <a class="graphic graphic_table graphicRef62038" href="/z/d/graphic/62038.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sporadic, infrequent episodes (&lt;3 episodes/year)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonpregnant individual
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild to moderate signs/symptoms (ie, minimal or localized erythema and/or edema, no fissures)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Probable infection with
         <em>
          Candida
         </em>
         <em>
          albicans
         </em>
         (approximately 90 percent of patients with VVC have albicans-related infection)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunocompetent individual
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1065225812">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uncomplicated VVC can be treated with oral azoles, topical azoles, and triterpenoid drugs  (
         <a class="graphic graphic_table graphicRef71686" href="/z/d/graphic/71686.html" rel="external">
          table 2
         </a>
         ). As all drugs have established efficacy, use of any is reasonable [
         <a href="#rid3">
          3-6
         </a>
         ]. After assessing patient preferences and prior response (if any), we generally proceed in the order presented below  (
         <a class="graphic graphic_algorithm graphicRef141434" href="/z/d/graphic/141434.html" rel="external">
          algorithm 1
         </a>
         ). Other factors include drug interactions, use criteria, availability, and cost.
        </p>
        <p class="headingAnchor" id="H131147485">
         <span class="h3">
          Oral fluconazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         We treat nonpregnant patients with oral
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         . Patients typically prefer oral rather than vaginal medications [
         <a href="#rid4">
          4,7
         </a>
         ] and efficacy is similar for oral and topical azoles. (See
         <a class="local">
          'Efficacy'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose
         </strong>
         –
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          Fluconazole
         </a>
         150 mg orally given once or twice.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Initial response is typically seen within 24 hours. In our experience, patients with mild symptoms respond with one dose but patients with moderate symptoms often need a second dose taken 72 hours after the first dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          Fluconazole
         </a>
         maintains therapeutic concentrations in vaginal secretions for at least 72 hours after the ingestion of a single 150 mg tablet [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Side effects and drug interactions
         </strong>
         –
         <strong>
         </strong>
         Side effects of single-dose
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         (150 mg) tend to be mild and infrequent. Oral fluconazole may cause gastrointestinal intolerance, headache, rash, and transient liver function abnormalities. Although fluconazole interacts with multiple drugs, interactions are rare at the dose used to treat VVC.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Azole resistance
         </strong>
         – Azole resistance is uncommon for vaginitis caused by
         <em>
          C. albicans
         </em>
         [
         <a href="#rid9">
          9,10
         </a>
         ]. In vitro susceptibility tests are typically not indicated unless compliant patients with a culture-proven diagnosis have no response to adequate therapy.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">
          Oteseconazole
         </a>
         is another oral azole but is indicated only for patients who are
         <strong>
          not
         </strong>
         of reproductive potential and have RVVC (ie, not for use in sporadic or acute VVC infections) [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/141182.html" rel="external">
          "Candida vulvovaginitis in adults: Recurrent infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3947936371">
         <span class="h3">
          Topical azoles
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple topical azole products are available  (
         <a class="graphic graphic_table graphicRef71686" href="/z/d/graphic/71686.html" rel="external">
          table 2
         </a>
         ). No regimen has demonstrated superiority over another; selection is based on patient preferences around duration of treatment, prior response history, and availability. While vulvar treatment can improve vulvar symptoms, vaginal therapy is necessary to eradicate the vaginal reservoir of organisms and fully treat the disease [
         <a href="#rid12">
          12
         </a>
         ]. Topical therapy starts to relieve symptoms within hours.
        </p>
        <p>
         In randomized trials, oral and topical antimycotic drugs achieved comparable clinical cure rates, which are in excess of 90 percent; short-term mycologic cure is slightly lower (70 to 80 percent) [
         <a href="#rid4">
          4,13,14
         </a>
         ]. (See
         <a class="local">
          'Efficacy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H581102027">
         <span class="h3">
          Triterpenoid (ibrexafungerp)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         (commercial name Brexafemme) is a single-day multi-dose oral triterpenoid antifungal for use in nonpregnant patients with uncomplicated VVC [
         <a href="#rid15">
          15
         </a>
         ]. Unlike
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         , which inhibits fungal growth, ibrexafungerp kills
         <em>
          Candida
         </em>
         species by inhibiting formation of the fungal cell wall and is the first in its class (glucan synthase inhibitor) [
         <a href="#rid16">
          16,17
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prescribing information
         </strong>
         –
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         is prescribed as four tablets of 150 mg each [
         <a href="#rid15">
          15
         </a>
         ]. The patient should take two tablets by mouth twice in one day (ie, two in the morning and two at night).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient selection
         </strong>
         – Patients who may benefit from this therapy include those who are allergic to
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         and other triazoles, do not tolerate fluconazole or other triazoles, and/or have
         <em>
          Candida
         </em>
         infections that are resistant to fluconazole.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug interactions
         </strong>
         – Individuals using strong CYP3A inhibitors should reduce the dose to 150 mg twice in one day because of increased exposure to
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         . Individuals taking strong or moderate CYP3A inducers may have significantly reduced exposure and are advised to use another antifungal treatment or avoid cotreatment with ibrexafungerp and CYP3A inducers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy and lactation
         </strong>
         – The drug should
         <strong>
          not
         </strong>
         be given to pregnant individuals because of concern for fetal harm based on animal studies [
         <a href="#rid15">
          15
         </a>
         ]. Human data for both pregnancy and lactation are lacking.
        </p>
        <p>
        </p>
        <p>
         While the single-day regimen and oral dosing are appealing, the cost may be prohibitive for many. Discussion of extended
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         treatment for RVVC is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/141182.html" rel="external">
          "Candida vulvovaginitis in adults: Recurrent infection", section on 'Ibrexafungerp'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2724474914">
         <span class="h2">
          Efficacy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Comparison of azoles
         </strong>
         – Both oral and topical azole treatment result in symptom relief and resolution of infection in approximately 80 to 90 percent of patients who complete therapy [
         <a href="#rid4">
          4,5
         </a>
         ]. Rates vary by definition of cure and duration of follow-up, among other variables [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A meta-analysis of 26 trials, including 5007 participants, reported the following outcome data for oral (mainly
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         ) compared with topical azoles [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical cure
         </strong>
         – Defined as absence of symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Short-term
         <strong>
         </strong>
         (5 to 15 days) clinical cure rates: Oral 79 percent, topical 77 percent, odds ratio (OR) 1.14, 95% CI 0.91-1.43, n = 1859.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Long-term cure (2 to 12 weeks) clinical rates: Oral 85 percent, topical 84 percent, OR 1.07, 95% CI 0.77-1.50, n = 1042.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mycological cure
         </strong>
         – Defined as no evidence of vulvovaginal candidiasis by either mycological culture or microscopy.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Short-term (5 to 15 days) mycological cure rates: Oral 83 percent, topical 80 percent, OR 1.24, 95% CI 1.03-1.50, n = 3057.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Long-term cure (2 to 12 weeks) mycological rates: Oral 72 percent, topical 66 percent, OR 1.29, 95% CI 1.05-1.60, n = 1661.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         – Ibrexafungerp is more effective than placebo and, in one small trial, oral
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         [
         <a href="#rid3">
          3,18,19
         </a>
         ]. Larger trials are required to determine superiority of one drug treatment compared with the other.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Placebo comparison
         </strong>
         – Clinical trials have demonstrated
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         results in higher clinical cure rates compared with placebo [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Oral
         </strong>
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         <strong>
          comparison
         </strong>
         – A trial comparing
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         (300 mg bid for one day) with single-dose oral fluconazole in 62 patients reported [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          10-day test of cure
         </strong>
         – Clinical cure rates of 52 versus 58 percent, respectively, and mycological cure rates of 63 percent for both. Clinical cure was defined as "complete resolution of vulvovaginal signs and symptoms" and mycological cure indicated negative fungal cultures. Differences in patient entry and assessment criteria likely contributed to lower clinical and mycological cure rates compared with the azole meta-analysis discussed above [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          25-day follow-up of clinical responders
         </strong>
         – Continued response rates of 41 versus 42 percent and mycological eradication rates of 48 versus 38 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In post-hoc analysis, rates of clinical improvement were similar at 10-day test of cure (70 versus 71 percent) but at 25 days were 82 percent for
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         and 58 percent for oral
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         . Rescue medication was used less often in the ibrexafungerp group compared with oral fluconazole (4 versus 29 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2481024416">
         <span class="h1">
          COMPLICATED INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with complicated infection includes those who are pregnant, have severe symptoms or immunocompromise, have infection with non-albicans
         <em>
          Candida
         </em>
         (NAC) species, or have recurrent infection (≥3 test-confirmed infections per year)  (
         <a class="graphic graphic_table graphicRef62038" href="/z/d/graphic/62038.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid2">
          2,5
         </a>
         ]. Treatment of recurrent infection is discussed in detail in related content  (
         <a class="graphic graphic_algorithm graphicRef141431" href="/z/d/graphic/141431.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/141182.html" rel="external">
          "Candida vulvovaginitis in adults: Recurrent infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3744278019">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of pregnant people is primarily indicated for relief of symptoms; vaginal candidiasis is not associated with adverse pregnancy outcomes [
         <a href="#rid20">
          20
         </a>
         ]. Beyond symptom relief, one European guideline advises treating all colonized pregnant persons in the third trimester to reduce the rates of oral thrush and diaper dermatitis in newborns [
         <a href="#rid21">
          21
         </a>
         ]. VVC occurring during pregnancy is considered a complicated infection because pregnancy impacts choice of treatment based on concerns for adverse fetal outcomes and longer courses of therapy are typically needed, rather than the disease being inherently more severe or complicated in pregnant persons.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial treatment
         </strong>
         – We suggest application of a topical imidazole vaginally for seven days rather than treatment with oral antifungal agents (azoles or
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         ) because of potential risks with these drugs  (
         <a class="graphic graphic_algorithm graphicRef141479" href="/z/d/graphic/141479.html" rel="external">
          algorithm 3
         </a>
         ) [
         <a href="#rid5">
          5,11,15,22-26
         </a>
         ]. While we typically use
         <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">
          clotrimazole
         </a>
         or
         <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">
          miconazole
         </a>
         , others are reasonable.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">
          Clotrimazole
         </a>
         1% cream – One applicatorful (approximately 5 g) in the vagina daily for seven days
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Or
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">
          Miconazole
         </a>
         2% cream – One applicatorful (approximately 5 g) in the vagina daily for seven days
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Or
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">
          Nystatin
         </a>
         suppository 100,000 units – One suppository in the vagina nightly for 14 nights [
         <a href="#rid27">
          27
         </a>
         ]. Suppositories can be prepared by a compounding pharmacy if not commercially available. Potential side effects include burning, redness, and irritation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment duration
         </strong>
         – We begin with the treatment durations listed above, but some pregnant patients may require longer treatment courses of 10 to 14 days to fully resolve symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          RVVC in pregnancy
         </strong>
         –
         <strong>
         </strong>
         Pregnant patients with RVVC (defined as ≥3 test-confirmed infections per year) use an induction regimen and then begin maintenance therapy for continued suppression of symptoms  (
         <a class="graphic graphic_algorithm graphicRef141478" href="/z/d/graphic/141478.html" rel="external">
          algorithm 4
         </a>
         ). Detailed discussion of RVVC in pregnancy is presented in related content. (See
         <a class="medical medical_review" href="/z/d/html/141182.html" rel="external">
          "Candida vulvovaginitis in adults: Recurrent infection", section on 'Pregnant'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drugs to avoid in pregnancy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Oral
         </strong>
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         – We avoid oral fluconazole during pregnancy, particularly in the first trimester, because it may increase the risk of miscarriage and its impact on congenital anomalies is unclear [
         <a href="#rid15">
          15,22,24
         </a>
         ]. Oral fluconazole therapy does not appear to increase the risk of stillbirth or neonatal death [
         <a href="#rid24">
          24,28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Pregnancy loss
         </strong>
         – Two large observational studies reported an association between oral
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         and pregnancy loss [
         <a href="#rid22">
          22,24
         </a>
         ]. While two earlier observational studies totaling just over 1500 patients did not report an association [
         <a href="#rid29">
          29,30
         </a>
         ], the larger studies likely had greater power to detect an increase in miscarriage risk.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         A cohort study comparing 3315 pregnant persons who received oral
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         (150 to 300 mg between 7 and 22 weeks) with matched control patients reported increased risk of pregnancy loss with fluconazole exposure, although the absolute risk remained low (4.4 versus 4.2 percent, respectively, hazard ratio 0.14, 95% CI 1.23-1.77) [
         <a href="#rid22">
          22
         </a>
         ]. Stillbirth risk did not differ among the groups, although stillbirth was a relatively rare outcome.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         A subsequent larger population cohort study that evaluated over 320,000 pregnancies reported increased risk of pregnancy loss with
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         exposure during early pregnancy [
         <a href="#rid24">
          24
         </a>
         ]. While the absolute risk remained small, a dose-dependent relationship was reported (≤150 mg: pregnancy loss rates 1.2 versus 0.5 percent, adjusted odds ratio [aOR] 2.23, 95% CI 1.96-2.54 and &gt;150 mg: pregnancy loss rates 0.9 versus 0.2 percent, aOR 3.20, 95% CI 2.73-3.75).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Congenital anomalies
         </strong>
         – The impact of
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         on congenital anomalies is difficult to assess, in part because of the variability across studies for drug dose, gestational age, duration of exposure, method of exposure assessment, and the lack of consistency across the reported congenital anomalies. Overall, the data appear reassuring for people who took low-dose fluconazole (150 mg) before realizing that they were pregnant [
         <a href="#rid29">
          29-36
         </a>
         ], although an increased risk of cardiac and musculoskeletal anomalies cannot be definitively excluded, especially at higher doses [
         <a href="#rid24">
          24,37,38
         </a>
         ]. In the United States Medicaid Analytic eXtract database including over 1.9 million pregnancies, the reported overall association would result in approximately 12 additional musculoskeletal anomalies per 10,000 exposed pregnancies [
         <a href="#rid37">
          37
         </a>
         ]. Additionally, case reports have described a pattern of congenital anomalies (abnormalities of cranium, face, bones, and heart) after first-trimester exposure to high-dose fluconazole therapy (400 to 800 mg/day) [
         <a href="#rid39">
          39,40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">
          Oteseconazole
         </a>
         – Oteseconazole, an oral azole, is
         <strong>
          not
         </strong>
         for use in patients who are pregnant, could become pregnant, or are lactating because animal data suggest potential for fetal and/or infant harm [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         – Ibrexafungerp is
         <strong>
          not
         </strong>
         for use in pregnancy because of concerns for fetal harm based on animal data [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9978" href="/z/d/drug information/9978.html" rel="external">
          Terconazole
         </a>
         – Terconazole is a triazole drug used topically that is absorbed through the vagina. Based on concerns for embryotoxicity in rabbits and rats, terconazole labelling states "it should not be in the first trimester" unless use is essential to the welfare of the patient and it "may be used during the second and third trimester if potential benefits outweigh the possible risks to the fetus" [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">
          Vaginal boric acid
         </a>
         – We do not use vaginal boric acid in pregnancy as risk of harm is unknown. Boric acid can cause death if ingested orally.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H719561344">
         <span class="h2">
          Severe symptoms or immunocompromise
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with severe symptoms (eg, extensive vulvovaginal involvement, skin fissures, and/or tissue edema) or immunocompromise (eg, immunosuppressive drugs, poorly controlled diabetes) generally need longer courses of oral or topical antimycotic drugs [
         <a href="#rid5">
          5
         </a>
         ]. It is unknown whether one route is more effective than the other  (
         <a class="graphic graphic_algorithm graphicRef141431" href="/z/d/graphic/141431.html" rel="external">
          algorithm 2
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preferred
         </strong>
         – For treatment of complicated infections, we suggest treatment with oral
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         150 mg for two to three sequential doses, 72 hours apart; patients with more severe infections receive three doses  (
         <a class="graphic graphic_table graphicRef50932" href="/z/d/graphic/50932.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid5">
          5,6
         </a>
         ]. In our clinical practice, patients do well with this approach and generally prefer oral to vaginal therapy, as topical therapies may exacerbate vulvovaginal discomfort. Additionally, oral fluconazole is more readily available and lower cost than
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         . However, treatment with topical azoles for 7 to 14 days  (
         <a class="graphic graphic_table graphicRef71686" href="/z/d/graphic/71686.html" rel="external">
          table 2
         </a>
         ) or ibrexafungerp is reasonable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alternates
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         – Ibrexafungerp (150 mg tablets, two tablets taken orally twice in one day) may be prescribed for individuals with severe VVC [
         <a href="#rid18">
          18,19
         </a>
         ]. The need for repeat dosing, or optimal dosing interval for repeat therapy, is not yet known. Full discussion of ibrexafungerp dosing and contraindications is presented above. (See
         <a class="local">
          'Triterpenoid (ibrexafungerp)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Topical azole therapy
         </strong>
         – Observational series report that patients who choose topical azole therapy benefit from 7 to 14 days of treatment (eg,
         <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">
          clotrimazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">
          miconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9978" href="/z/d/drug information/9978.html" rel="external">
          terconazole
         </a>
         ) rather than a one- to three-day course [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adjunct topical steroids
         </strong>
         – For severe
         <em>
          Candida
         </em>
         vulvar inflammation (ie, extensive tissue erythema and/or edema), topical corticosteroids can be applied to the vulva for 48 hours until the antifungals exert their effect. Topical corticosteroids can be given as a separate agent (eg,
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         ) or as combination therapy (eg, clotrimazole-betamethasone or
         <a class="drug drug_general" data-topicid="9713" href="/z/d/drug information/9713.html" rel="external">
          nystatin-triamcinolone
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIV infection
         </strong>
         – Treatment of patients with HIV is the same as for those without infection; the approach is based on presence of uncomplicated or complicated disease. Individuals with HIV infection generally respond to short-course therapy and do not need extended treatment unless symptoms are particularly severe or recurrent [
         <a href="#rid5">
          5,42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – While both single and two-dose
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         treatment improve symptoms, the two-dose regimen results in higher clinical cure rates. In a trial that randomized 556 patients with severe or RVVC to single dose or two sequential doses of fluconazole (150 mg), the two-dose regimen resulted in significantly higher clinical cure/improvement rates on day 14 (85 versus 94 percent) and day 35 (67 versus 80 percent) in those with severe, but not recurrent, disease [
         <a href="#rid42">
          42
         </a>
         ]. However, the response to therapy was lower in the 8 percent infected with NAC.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3076767122">
         <span class="h2">
          Non-albicans Candida species
         </span>
        </p>
        <p class="headingAnchor" id="H2731874539">
         <span class="h3">
          Microbiology and clinical significance
         </span>
         <span class="headingEndMark">
          —
         </span>
         NAC species include
         <em>
          C. glabrata
         </em>
         (most common),
         <em>
          C. krusei
         </em>
         ,
         <em>
          C. tropicalis
         </em>
         ,
         <em>
          S. cerevisiae,
         </em>
         and
         <em>
          C. parapsilosis,
         </em>
         among others
         <em>
         </em>
         [
         <a href="#rid43">
          43
         </a>
         ]. Azole treatment of
         <em>
          C. glabrata
         </em>
         is often unsuccessful, and
         <em>
          C. krusei
         </em>
         and
         <em>
          S. cerevisiae
         </em>
         are generally inherently resistant to
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         .
         <em>
          C. tropicalis
         </em>
         is typically azole sensitive. As azole therapy is unlikely to treat NAC, infection with NAC species have been associated with increased office visits for recurring vulvovaginal complaints when compared with
         <em>
          C. albicans
         </em>
         [
         <a href="#rid44">
          44
         </a>
         ] and have been observed in 10 to 20 percent of patients with RVVC [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1220949165">
         <span class="h3">
          Candida glabrata
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          C. glabrata
         </em>
         is a frequent vaginal colonizer that has low vaginal virulence and rarely causes symptoms, even when identified by culture. Therefore, we make every effort to exclude other causes of symptoms and only treat
         <em>
          C. glabrata
         </em>
         vaginitis when all other potential sources of the vaginal symptoms have been addressed [
         <a href="#rid5">
          5
         </a>
         ]. When treatment is elected,
         <em>
          C. glabrata
         </em>
         does not respond to typical first-line therapies because of inherent resistance or low-level drug susceptibility [
         <a href="#rid43">
          43,45-47
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preferred
         </strong>
         –
         <strong>
         </strong>
         Although studies specific to treatment of
         <em>
          C. glabrata are
         </em>
         limited, we prefer treatment with
         <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">
          vaginal boric acid
         </a>
         or vaginal
         <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">
          nystatin
         </a>
         as these drugs are reasonably available, generally well tolerated, and have some supporting evidence.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">
          Vaginal boric acid
         </a>
         – Vaginal boric acid 600 mg capsule nightly for two to three weeks resolves symptoms in roughly 70 percent of patients with confirmed
         <em>
          C. glabrata
         </em>
         (
         <a class="graphic graphic_table graphicRef50932" href="/z/d/graphic/50932.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid5">
          5,48-50
         </a>
         ]. We prefer initial treatment with vaginal boric acid for nonpregnant persons because it is reasonably effective, low cost, and accessible. However, we do not use vaginal boric acid in pregnant patients as safety has not been established.
         <strong>
          Boric acid capsules can be fatal if swallowed
         </strong>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">
          Nystatin
         </a>
         – Nystatin suppository 100,000 units in vagina at night for 14 to 30 nights (duration varies with disease severity) [
         <a href="#rid27">
          27,49,51
         </a>
         ]. At least one consensus guideline advises topical nystatin for
         <em>
          C. glabrata
         </em>
         [
         <a href="#rid21">
          21
         </a>
         ]. Although there are limited data to support nystatin treatment of
         <em>
          C. glabrata
         </em>
         , advantages include that nystatin is generally well tolerated, low cost, and accessible. Potential side effects include burning, redness, and irritation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Minimal data
         </strong>
         –
         <strong>
         </strong>
         As there are minimal supporting data for the treatments below, selection is mainly based on availability (ie, access, cost) and adverse effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Topical
         </strong>
         <strong>
          flucytosine
         </strong>
         <strong>
          cream
         </strong>
         – Topical
         <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">
          flucytosine
         </a>
         cream 16%, 5 g dose, intravaginally at night for 14 nights. A retrospective review of patients with culture-confirmed
         <em>
          C. glabrata
         </em>
         reported 27 of 30 patients (90 percent) had a successful outcome after they had not responded to
         <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">
          vaginal boric acid
         </a>
         and azole therapy [
         <a href="#rid49">
          49
         </a>
         ]. Flucytosine cream may require a compounding pharmacy to construct a cream from oral capsules, which limits access and increases cost. Highest efficacy is seen when used in combination with topical amphotericin B, as below [
         <a href="#rid50">
          50,52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Amphotericin B suppository
         </strong>
         – Amphotericin B, 50 mg suppository, intravaginally at night for 14 nights. An observational study of 10 patients with persistent NAC infection despite conventional treatment reported that seven patients were successfully treated with 50 mg vaginal suppository at night for 14 nights [
         <a href="#rid52">
          52
         </a>
         ]. While combined treatment with both amphotericin B and
         <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">
          nystatin
         </a>
         100,000 mg suppositories has been reported, both drugs are polyene compounds and their combined use is of unclear benefit [
         <a href="#rid50">
          50,51
         </a>
         ]. Amphotericin B suppositories are not commercially available and require manufacture by a compounding pharmacy, which limits access and increases cost [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         – Ibrexafungerp is single-day oral triterpenoid antifungal for use in postmenarchal females with VVC [
         <a href="#rid15">
          15
         </a>
         ]. While it may be a treatment option for
         <em>
          C. glabrata
         </em>
         , supporting data for this population are lacking and the optimal drug dose and duration are uncertain. If used, the dosing regimen would be the same as for uncomplicated infection. Ibrexafungerp is not for use during pregnancy or lactation. (See
         <a class="local">
          'Triterpenoid (ibrexafungerp)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          Voriconazole
         </a>
         –
         <strong>
         </strong>
         As there are scant data regarding use of oral voriconazole for
         <em>
          C. glabrata
         </em>
         vaginitis, it should not be used to treat VVC unless all other topical and systemic antifungal therapies have failed [
         <a href="#rid51">
          51
         </a>
         ]. Animal data (mice) and anecdotal reports suggest occasional cures, but there is potential for hepatic toxicity, arrhythmias, and QT prolongation [
         <a href="#rid53">
          53,54
         </a>
         ]. When used to treat VVC, oral voriconazole 200 mg is given orally twice daily for two weeks [
         <a href="#rid55">
          55
         </a>
         ]. Dose adjustments are required for hepatic impairment. Treatment duration depends on patient response. The drug should be taken at least one hour before or after a meal [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Combined drug therapy
         </strong>
         – Multi-drug treatment has been reported using both sequential and simultaneous therapies. Supporting data are limited to small case reports [
         <a href="#rid50">
          50,56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Generally avoided
         </strong>
         – Azole therapy commonly results in treatment failure (around 50 percent) for patients with
         <em>
          C. glabrata
         </em>
         vaginitis [
         <a href="#rid43">
          43,48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H120118866">
         <span class="h3">
          Candida krusei
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          C. krusei
         </em>
         is mostly resistant to
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         [
         <a href="#rid43">
          43,57
         </a>
         ] but is usually susceptible to topical azole creams and suppositories, such as
         <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">
          clotrimazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">
          miconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9978" href="/z/d/drug information/9978.html" rel="external">
          terconazole
         </a>
         (
         <a class="graphic graphic_table graphicRef50932" href="/z/d/graphic/50932.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid51">
          51
         </a>
         ]. We treat with any of these topical azoles for 7 to 14 days  (
         <a class="graphic graphic_table graphicRef71686" href="/z/d/graphic/71686.html" rel="external">
          table 2
         </a>
         ). It is also likely to respond to oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         or
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         (itraconazole 200 mg orally twice daily for 7 to 14 days or ketoconazole 400 mg orally daily for 7 to 14 days), but these oral agents have variable toxicity, so topical therapy is advised for first-line therapy. Idiosyncratic hepatotoxicity secondary to ketoconazole therapy is a concern but rare in this setting. In vitro susceptibility testing is indicated in compliant patients with culture-proven diagnosis of
         <em>
          C. krusei
         </em>
         and no response to a conventional course of one of these nonfluconazole therapies. For patients who have not responded adequately to azole treatment, oral
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         may be tried, but the optimal dose and duration are not known.
        </p>
        <p class="headingAnchor" id="H1163596085">
         <span class="h3">
          Other non-albicans species
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal treatment of other NAC species is unknown. Treatment options include topical
         <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">
          clotrimazole
         </a>
         (100 mg in vagina daily for 14 days),
         <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">
          nystatin
         </a>
         (as above), or
         <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">
          vaginal boric acid
         </a>
         (as above) [
         <a href="#rid43">
          43
         </a>
         ]. Other combination therapies have also been reported [
         <a href="#rid50">
          50
         </a>
         ]. We prefer vaginal boric acid for patients who have not responded to azole treatments [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2633890073">
         <span class="h2">
          Recurrent infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         RVVC is defined as three or more episodes of confirmed symptomatic fungal infection within one year [
         <a href="#rid5">
          5,58
         </a>
         ]. Discussion of RVVC management, including azole-resistant infection, is presented in detail in related content. (See
         <a class="medical medical_review" href="/z/d/html/141182.html" rel="external">
          "Candida vulvovaginitis in adults: Recurrent infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2660412661">
         <span class="h1">
          FOLLOW-UP CARE AND SYMPTOM RECURRENCE
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment response
         </strong>
         – Uncomplicated infections usually respond to treatment within a couple of days; complicated infection may require one to two weeks. There is no medical contraindication to sexual intercourse during treatment, but it may be uncomfortable until inflammation improves. Treatment of sexual partners is not indicated. (See
         <a class="local">
          'Sex partners'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptom recurrence
         </strong>
         –
         <strong>
         </strong>
         Patients with symptom recurrence undergo repeat evaluation and testing to confirm fungal infection and exclude other causes and/or mixed infection. Correct and consistent treatment of the initial infection is also confirmed. (See
         <a class="medical medical_review" href="/z/d/html/5452.html" rel="external">
          "Candida vulvovaginitis: Clinical manifestations and diagnosis", section on 'Diagnostic approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Repeat treatment
         </strong>
         – Patients with confirmed symptomatic VVC are again treated based on presence of uncomplicated or complicated infection. Patients who are candidates for
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         may prefer this drug as an alternate to
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         . Patients with ≥3 confirmed VVC episodes in 12 months are treated for RVVC. (See
         <a class="medical medical_review" href="/z/d/html/141182.html" rel="external">
          "Candida vulvovaginitis in adults: Recurrent infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2345660701">
         <span class="h1">
          PREVENTIVE AND COMPLEMENTARY TREATMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple VVC preventive treatments have been tried with little success, including oral
         <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">
          nystatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9541" href="/z/d/drug information/9541.html" rel="external">
          lactobacillus
         </a>
         (oral or vaginal), other probiotics, and garlic [
         <a href="#rid51">
          51,59-61
         </a>
         ]. Tea tree oil or vapor may have anti-
         <em>
          Candida
         </em>
         activity but clinical correlation is needed [
         <a href="#rid62">
          62,63
         </a>
         ].
        </p>
        <p>
         One exception is the patient who develops symptomatic yeast infection during or immediately after antibiotic therapy. For these patients,
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         (150 mg orally) at the start and end of antibiotic therapy may prevent post-antibiotic vulvovaginitis [
         <a href="#rid64">
          64
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5452.html" rel="external">
          "Candida vulvovaginitis: Clinical manifestations and diagnosis", section on 'Risk factors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3129799991">
         <span class="h1">
          UNIQUE POPULATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H527382090">
         <span class="h2">
          Sex partners
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although sexual transmission of
         <em>
          Candida
         </em>
         species can occur, we and others do not recommend treatment of asymptomatic sex partners since sexual activity is not a significant cause of infection or reinfection [
         <a href="#rid5">
          5,65
         </a>
         ]. The bulk of evidence from randomized trials does
         <strong>
          not
         </strong>
         support treatment of sexual partners [
         <a href="#rid66">
          66-68
         </a>
         ], although this approach is somewhat controversial in individuals with confirmed recurrent VVC. One organization states no recommendation can be made for treating sex partners of patients with complicated (including recurrent) VVC as data specific to this population are lacking [
         <a href="#rid5">
          5
         </a>
         ]. Treatment of recurrent VVC is presented in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/141182.html" rel="external">
          "Candida vulvovaginitis in adults: Recurrent infection"
         </a>
         .)
        </p>
        <p>
         Treatment of symptomatic males is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6876.html" rel="external">
          "Balanitis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2025432592">
         <span class="h2">
          Lactating patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both topical azoles and oral
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         are compatible with breastfeeding but not all drugs have been studied.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nystatin
         </strong>
         –
         <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">
          Nystatin
         </a>
         is very poorly absorbed with oral ingestion (ie, the amount absorbed by the milk-fed infant is minimal) and thus the drug is compatible for use by lactating individuals [
         <a href="#rid69">
          69,70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluconazole
         </strong>
         –
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          Fluconazole
         </a>
         is considered acceptable for use in lactating patients as the "amount excreted into breastmilk is less than the neonatal fluconazole dosage," and no adverse effects have been reported in breastfed infants or infants treated with parenteral fluconazole [
         <a href="#rid71">
          71-73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other topical azoles
         </strong>
         –
         <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">
          Miconazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">
          clotrimazole
         </a>
         are minimally absorbed from the vagina and thus are considered reasonable for use in lactating patients [
         <a href="#rid74">
          74,75
         </a>
         ]. As
         <a class="drug drug_general" data-topicid="9178" href="/z/d/drug information/9178.html" rel="external">
          butoconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9998" href="/z/d/drug information/9998.html" rel="external">
          tioconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9978" href="/z/d/drug information/9978.html" rel="external">
          terconazole
         </a>
         have not been studied during lactation, other drugs may be preferred [
         <a href="#rid76">
          76-78
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         and
         <a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">
          oteseconazole
         </a>
         are
         <strong>
          not
         </strong>
         used in pregnant or lactating patients because of concern for fetal and/or infant harm based on animal studies [
         <a href="#rid11">
          11,15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H265513491">
         <span class="h2">
          Allergy to fluconazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          Fluconazole
         </a>
         allergy is uncommon in our practice the but the overall prevalence of fluconazole allergy in patients with acute VVC is unknown [
         <a href="#rid51">
          51
         </a>
         ]. Fluconazole allergy can present with typical allergic symptoms that range in severity and include rash and, occasionally, angioedema. It is difficult to distinguish between isolated fluconazole allergy versus allergy to the entire azole class. Therefore, other oral azoles such as
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         (commercial name Nizoral) or
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         (commercial name Sporanox) should not be prescribed to patients with true fluconazole allergy. Discussion with an allergist is recommended. There are no data on the efficacy of fluconazole desensitization, which is theoretically possible.
        </p>
        <p>
         Treatment for patients with
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         allergy (severe rash and/or angioedema) and acute confirmed VVC include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical azole drugs
         </strong>
         – Either
         <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">
          miconazole
         </a>
         or
         <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">
          clotrimazole
         </a>
         can be prescribed, 500 to 1500 mg, in the vagina once  (
         <a class="graphic graphic_table graphicRef71686" href="/z/d/graphic/71686.html" rel="external">
          table 2
         </a>
         ). In general, miconazole is available as 100 mg or 200 mg vaginal suppositories while clotrimazole is available as 100 mg vaginal tablet; total dose of 500 to 1500 mg per treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nystatin
         </strong>
         –
         <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">
          Nystatin
         </a>
         suppository 100,000 units in the vagina daily for seven days. Nystatin is a polyene antifungal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ibrexafungerp
         </strong>
         –
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         is an oral triterpenoid antifungal for use in nonpregnant patients. Dosing is described above. (See
         <a class="local">
          'Triterpenoid (ibrexafungerp)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">
          Vaginal boric acid
         </a>
         –
         <strong>
          Vaginal
         </strong>
         boric acid 600 mg capsule in vagina daily for seven days.
         <strong>
          Boric acid can cause death if consumed orally.
         </strong>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2852441528">
         <span class="h2">
          Females taking tamoxifen
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          Tamoxifen
         </a>
         is an estrogen receptor blocker and is widely used in patients with breast cancer. Paradoxically, tamoxifen may result in "agonist" or estrogen-like benign manifestations in the vagina, characterized by mild discharge and increased risk of VVC. We treat individuals taking tamoxifen who also have recurrent VVC, which is discussed separately, with maintenance
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         therapy. (See
         <a class="medical medical_review" href="/z/d/html/141182.html" rel="external">
          "Candida vulvovaginitis in adults: Recurrent infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3739650669">
         <span class="h2">
          Male partners with postcoital hypersensitivity reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uncommonly, male partners of individuals with vaginal
         <em>
          Candida
         </em>
         colonization can develop immediate postcoital itching and burning with redness and a rash of the penis. This postcoital syndrome probably represents an acute hypersensitivity reaction to
         <em>
          Candida
         </em>
         organisms or antigens in the partner's vagina, even in the absence of symptomatic vulvovaginitis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Condoms
         </strong>
         – Condom use (internal or external) typically prevents symptoms. (See
         <a class="medical medical_review" href="/z/d/html/5463.html" rel="external">
          "External (formerly male) condoms"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5471.html" rel="external">
          "Internal (formerly female) condoms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antifungal treatment for female sex partner
         </strong>
         – Males with recurrent postcoital symptoms benefit from immediate topical antimycotic therapy but symptoms will recur with next exposure to
         <em>
          Candida
         </em>
         organisms from the lower genital tract of the female sexual partner. This often requires the female partner to follow a long-term maintenance antimycotic regimen. (See
         <a class="medical medical_review" href="/z/d/html/141182.html" rel="external">
          "Candida vulvovaginitis in adults: Recurrent infection", section on 'Fluconazole'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptom reduction
         </strong>
         – A postcoital shower and application of a topical low-potency corticosteroid to the penis may provide symptomatic relief within 12 to 24 hours  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 4
         </a>
         ). Penile cultures may remain positive for
         <em>
          Candida
         </em>
         despite normal physical findings.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2341266606">
         <span class="h2">
          Incidental finding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of
         <em>
          Candida
         </em>
         identified on a Pap smear of an asymptomatic person is not indicated because up to 20 percent of reproductive-aged women will be colonized with
         <em>
          Candida
         </em>
         species [
         <a href="#rid79">
          79,80
         </a>
         ]. Similarly, individuals with
         <em>
          Candida
         </em>
         noted on an intrauterine device (IUD) that was cultured after removal do not require treatment in the absence of symptoms.
        </p>
        <p class="headingAnchor" id="H937873643">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111629.html" rel="external">
          "Society guideline links: Gynecologic infectious diseases (non-sexually transmitted)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2517027129">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Whom to treat
         </strong>
         – The goal of treatment is to relieve symptoms. Asymptomatic individuals and sex partners do not require treatment. (See
         <a class="local">
          'Whom to treat'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Uncomplicated infection in nonpregnant patients
         </strong>
         – For nonpregnant individuals with uncomplicated vulvovaginal candidiasis (VVC)  (
         <a class="graphic graphic_table graphicRef62038" href="/z/d/graphic/62038.html" rel="external">
          table 1
         </a>
         ), we suggest a single dose of oral
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         (150 mg) rather than other oral, multidose, or topical azole regimens  (
         <a class="graphic graphic_algorithm graphicRef141434" href="/z/d/graphic/141434.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). While topical agents or
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         are reasonable alternatives, patients generally prefer single-dose therapy for simplicity and prefer oral to vaginal treatment. Additionally, ibrexafungerp may be limited by availability and cost. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy
         </strong>
         – For pregnant persons, we suggest a topical azole vaginally for seven days  (
         <a class="graphic graphic_algorithm graphicRef141479" href="/z/d/graphic/141479.html" rel="external">
          algorithm 3
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Longer duration of topical therapy is typically needed to fully resolve the infection.
         <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">
          Nystatin
         </a>
         suppositories are a reasonable alternative if available. Oral azoles are not typically used because case reports have described a pattern of congenital anomalies (abnormalities of cranium, face, bones, and heart) after first-trimester exposure to high-dose oral azole therapy (400 to 800 mg/day) and cohort studies have reported conflicting data on risk of miscarriage.
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         and
         <a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">
          oteseconazole
         </a>
         are contraindicated in pregnancy based on animal data. (See
         <a class="local">
          'Pregnancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe symptoms or immunocompromise
         </strong>
         –
         <strong>
         </strong>
         For people with severe symptoms or immunocompromise, we suggest oral
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         (150 mg) in two sequential doses given three days apart rather than single-dose oral fluconazole,
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         , or topical regimens (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <strong>
         </strong>
         While clinical trial data addressing these populations are limited, the rationale for the two-dose regimen rather than single-dose is that these patients have more severe infection and/or greater risk for recurrence. (See
         <a class="local">
          'Severe symptoms or immunocompromise'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Non-albicans
         </strong>
         <strong>
          <em>
           Candida
          </em>
         </strong>
         <strong>
          infections
         </strong>
         –
         <strong>
         </strong>
         In most cases, the species is not known and treatment of
         <em>
          Candida albicans
         </em>
         is assumed. In some patients, such as those who have not responded to previous azole treatment, species information is available.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For individuals with
         <em>
          Candida glabrata
         </em>
         infection who do not respond to azole therapy, we suggest intravaginal boric acid (600 mg capsule once daily at night for two weeks) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Alternative treatments include intravaginal
         <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">
          nystatin
         </a>
         suppository 100,000 units daily, intravaginal amphotericin B suppository,
         <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">
          flucytosine
         </a>
         cream,
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         , or
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         ; selection is driven by availability. (See
         <a class="local">
          'Candida glabrata'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For individuals with
         <em>
          Candida krusei
         </em>
         infection, we suggest treatment with a topical azole (cream or suppository) other than
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         (
         <a class="graphic graphic_table graphicRef50932" href="/z/d/graphic/50932.html" rel="external">
          table 3
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <em>
          C. krusei
         </em>
         is often resistant to fluconazole but is usually susceptible to
         <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">
          clotrimazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">
          miconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9978" href="/z/d/drug information/9978.html" rel="external">
          terconazole
         </a>
         and intermittently susceptible to oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         and oral
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         . (See
         <a class="local">
          'Candida krusei'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluconazole
         </strong>
         <strong>
          allergy
         </strong>
         – The incidence of
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         allergy in patients with acute VVC is unknown but uncommon. Individuals with fluconazole allergy, including angioedema and severe rash, can receive topical azoles such as
         <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">
          miconazole
         </a>
         or
         <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">
          clotrimazole
         </a>
         . (See
         <a class="local">
          'Allergy to fluconazole'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sex partners
         </strong>
         – We do not treat sex partners of patients with acute VVC since treatment has not been shown to improve cure or reduce recurrence rates. However, for patients with confirmed recurrent vulvovaginal candidiasis (RVVC), treatment of sex partners is controversial. (See
         <a class="local">
          'Sex partners'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           National guideline for the management of vulvovaginal candidiasis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect 1999; 75 Suppl 1:S19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nyirjesy P, Schwebke JR, Angulo DA, et al. Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis. Clin Infect Dis 2022; 74:2129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denison HJ, Worswick J, Bond CM, et al. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev 2020; 8:CD002845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watson MC, Grimshaw JM, Bond CM, et al. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev 2001; :CD002845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Houang ET, Chappatte O, Byrne D, et al. Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob Agents Chemother 1990; 34:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobel JD, Vazquez JA. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis 1996; 22:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrawal P, Yazdy G, Ghanem KG, et al. Vaginal Candida albicans: High Frequency of in Vitro Fluconazole Resistance in a Select Population-A Brief Note. Sex Transm Dis 2023; 50:121.
          </a>
         </li>
         <li class="breakAll">
          Vivjoa- oteseconazole capsule. US Food and Drug Administration (FDA) approved product information. Revised July 12, 2022. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on April 24, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donders GG, Sobel JD. Candida vulvovaginitis: A store with a buttery and a show window. Mycoses 2017; 60:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reef SE, Levine WC, McNeil MM, et al. Treatment options for vulvovaginal candidiasis, 1993. Clin Infect Dis 1995; 20 Suppl 1:S80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobel JD, Brooker D, Stein GE, et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. Am J Obstet Gynecol 1995; 172:1263.
          </a>
         </li>
         <li class="breakAll">
          Brexafemme (ibrexafungerp tablets). US Food and Drug Administration (FDA) approved product information. Revised November 30, 2022. US National Library of Medicine. https://www.dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on April 25, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sucher AJ, Thai A, Tran C, et al. Ibrexafungerp: A new triterpenoid antifungal. Am J Health Syst Pharm 2022; 79:2208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobel JD. Ibrexafungerp for the treatment of vulvovaginal candidiasis. Drugs Today (Barc) 2022; 58:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwebke JR, Sobel R, Gersten JK, et al. Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303). Clin Infect Dis 2022; 74:1979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobel R, Nyirjesy P, Ghannoum MA, et al. Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306). BJOG 2022; 129:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cotch MF, Hillier SL, Gibbs RS, Eschenbach DA. Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy. Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol 1998; 178:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farr A, Effendy I, Tirri BF, et al. Vulvovaginal Candidosis (Excluding Mucocutaneous Candidosis): Guideline of the German (DGGG), Austrian (OEGGG) and Swiss (SGGG) Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry Number 015/072, September 2020). Geburtshilfe Frauenheilkd 2021; 81:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mølgaard-Nielsen D, Svanström H, Melbye M, et al. Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth. JAMA 2016; 315:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daniel S, Rotem R, Koren G, et al. Vaginal antimycotics and the risk for spontaneous abortions. Am J Obstet Gynecol 2018; 218:601.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bérard A, Sheehy O, Zhao JP, et al. Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies. CMAJ 2019; 191:E179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young GL, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database Syst Rev 2001; :CD000225.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. Safety communication: Oral fluconazole in pregnancy. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm497656.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery (Accessed on April 26, 2016).
         </li>
         <li class="breakAll">
          United Kingdom National Guideline on the Management of Vulvovaginal Candidiasis (2007). https://www.bashhguidelines.org/media/1043/vvc-2007.pdf (Accessed on December 04, 2008).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasternak B, Wintzell V, Furu K, et al. Oral Fluconazole in Pregnancy and Risk of Stillbirth and Neonatal Death. JAMA 2018; 319:2333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mastroiacovo P, Mazzone T, Botto LD, et al. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol 1996; 175:1645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nørgaard M, Pedersen L, Gislum M, et al. Maternal use of fluconazole and risk of congenital malformations: A Danish population-based cohort study. J Antimicrob Chemother 2008; 62:172.
          </a>
         </li>
         <li class="breakAll">
          Fluconazole tablet. US Food and Drug Administration (FDA) approved product information. US National Library of Medicine. Available at: https://www.dailymed.nlm.nih.gov/dailymed/ (Accessed on May 25, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mølgaard-Nielsen D, Pasternak B, Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. N Engl J Med 2013; 369:830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jick SS. Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy 1999; 19:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorensen HT, Nielsen GL, Olesen C, et al. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br J Clin Pharmacol 1999; 48:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inman W, Pearce G, Wilton L. Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy. Eur J Clin Pharmacol 1994; 46:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilton LV, Pearce GL, Martin RM, et al. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998; 105:882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu Y, Bateman BT, Gray KJ, et al. Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study. BMJ 2020; 369:m1494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howley MM, Carter TC, Browne ML, et al. Fluconazole use and birth defects in the National Birth Defects Prevention Study. Am J Obstet Gynecol 2016; 214:657.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez-Rangel E, Van Allen MI. Prenatal exposure to fluconazole: An identifiable dysmorphic phenotype. Birth Defects Res A Clin Mol Teratol 2005; 73:919.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration Safety Communication: Use of long-term, high-dose Diflucan (fluconazole) during pregnancy may be associated with birth defects in infants. http://www.fda.gov/Drugs/DrugSafety/ucm266030.htm (Accessed on September 21, 2011).
         </li>
         <li class="breakAll">
          Terconazole- terconazole cream. US Food and Drug Administration (FDA) approved product information. Revised March, 2021. US National Library of Medicine. www.dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on April 26, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobel JD, Kapernick PS, Zervos M, et al. Treatment of complicated Candida vaginitis: Comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001; 185:363.
          </a>
         </li>
         <li class="breakAll">
          International Society for the Study of Vulvovaginal Disease recommendations for the diagnosis and treatment of vaginitis, Vieira-Baptista P, Stockdale CK, Sobel JS (Eds), Admedic, Lisbon 2023.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyd Tressler A, Markwei M, Fortin C, et al. Risks for Recurrent Vulvovaginal Candidiasis Caused by Non-Albicans Candida Versus Candida Albicans. J Womens Health (Larchmt) 2021; 30:1588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taghinejadi N, Andersson MI, Lord E. Recurrent vulvovaginal candidiasis with Candida glabrata - a management conundrum. Int J STD AIDS 2022; 33:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makanjuola O, Bongomin F, Fayemiwo SA. An Update on the Roles of Non-albicansCandida Species in Vulvovaginitis. J Fungi (Basel) 2018; 4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiasat N, Rezaei-Matehkolaei A, Mahmoudabadi AZ. Microsatellite Typing and Antifungal Susceptibility of Candida glabrata Strains Isolated From Patients With Candida Vaginitis. Front Microbiol 2019; 10:1678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobel JD, Chaim W. Treatment of Torulopsis glabrata vaginitis: Retrospective review of boric acid therapy. Clin Infect Dis 1997; 24:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: Use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003; 189:1297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powell AM, Gracely E, Nyirjesy P. Non-albicans Candida Vulvovaginitis: Treatment Experience at a Tertiary Care Vaginitis Center. J Low Genit Tract Dis 2016; 20:85.
          </a>
         </li>
         <li class="breakAll">
          Sobel J, Wayne State University, 2023, personal communication.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips AJ. Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories. Am J Obstet Gynecol 2005; 192:2009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González GM, Portillo OJ, Uscanga GI, et al. Therapeutic efficacy of voriconazole against a fluconazole-resistant Candida albicans isolate in a vaginal model. J Antimicrob Chemother 2009; 64:571.
          </a>
         </li>
         <li class="breakAll">
          Voriconazole tablet. US Food and Drug Administration (FDA) approved product information. Revised November 7, 2022. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on May 16, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris GC, Dean G, Soni S, et al. Outcomes and experiences of using oral voriconazole with or without concomitant topical agents to treat refractory vulvovaginal yeast infections. Int J STD AIDS 2022; 33:1134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White DJ, Habib AR, Vanthuyne A, et al. Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections. Sex Transm Infect 2001; 77:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jamiu AT, Albertyn J, Sebolai OM, Pohl CH. Update on Candida krusei, a potential multidrug-resistant pathogen. Med Mycol 2021; 59:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2016; 214:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie HY, Feng D, Wei DM, et al. Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database Syst Rev 2017; 11:CD010496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watson CJ, Grando D, Fairley CK, et al. The effects of oral garlic on vaginal candida colony counts: a randomised placebo controlled double-blind trial. BJOG 2014; 121:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Said MM, Watson C, Grando D. Garlic alters the expression of putative virulence factor genes SIR2 and ECE1 in vulvovaginal C. albicans isolates. Sci Rep 2020; 10:3615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandes L, Gonçalves B, Costa R, et al. Vapor-Phase of Essential Oils as a Promising Solution to Prevent Candida Vaginal Biofilms Caused by Antifungal Resistant Strains. Healthcare (Basel) 2022; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ervianti E, Damayanti, Purnamasari I, et al. Comparison of tea tree oil 5%, tea tree oil 10%, and nystatin inhibition zones against vaginal Candida isolates in pregnancy. J Infect Dev Ctries 2023; 17:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369:1961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farr A, Effendy I, Frey Tirri B, et al. Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k). Mycoses 2021; 64:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fong IW. The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourin Med 1992; 68:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shihadeh AS, Nawafleh AN. The value of treating the male partner in vaginal candidiasis. Saudi Med J 2000; 21:1065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bisschop MP, Merkus JM, Scheygrond H, van Cutsem J. Co-treatment of the male partner in vaginal candidosis: A double-blind randomized control study. Br J Obstet Gynaecol 1986; 93:79.
          </a>
         </li>
         <li class="breakAll">
          Nystatin. Drugs and Lactation Database (LactMed). US National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501241/ (Accessed on April 07, 2023).
         </li>
         <li class="breakAll">
          Nystatin cream. US Food and Drug Administration (FDA) approved product information. Revised February 18, 2023. US National Library of Medicine. www.dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on April 07, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.
          </a>
         </li>
         <li class="breakAll">
          Fluconazole. Drugs and Lactation Database (LactMed). Revised October 2018. US National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501922/?term=fluconazole (Accessed on April 07, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan YC, Koren G, Ito S, Bozzo P. Fluconazole use during breastfeeding. Can Fam Physician 2015; 61:875.
          </a>
         </li>
         <li class="breakAll">
          Miconazole. Drugs and Lactation Database (LactMed). Revised September 2022. US National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501234/ (Accessed on April 07, 2023).
         </li>
         <li class="breakAll">
          Clotrimazole. Drugs and Lactation Database (LactMed). Revised September 2022. US National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501211/ (Accessed on April 07, 2023).
         </li>
         <li class="breakAll">
          Tioconazole. Drugs and Lactation Database (LactMed). Revised October 2018. US National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501426/ (Accessed on April 07, 2023).
         </li>
         <li class="breakAll">
          Butoconazole. Drugs and Lactation Database (LactMed). Revised October 2018. US National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501424/ (Accessed on April 07, 2023).
         </li>
         <li class="breakAll">
          Terconazole. Drugs and Lactation Database (LactMed). Revised October 2018. US National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501428/ (Accessed on April 07, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldacre MJ, Watt B, Loudon N, et al. Vaginal microbial flora in normal young women. Br Med J 1979; 1:1450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tibaldi C, Cappello N, Latino MA, et al. Vaginal and endocervical microorganisms in symptomatic and asymptomatic non-pregnant females: Risk factors and rates of occurrence. Clin Microbiol Infect 2009; 15:670.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 115170 Version 37.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10616376" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : National guideline for the management of vulvovaginal candidiasis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9500475" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34555149" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32845024" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Sexually Transmitted Infections Treatment Guidelines, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11687165" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2360828" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8729224" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36630418" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Vaginal Candida albicans: High Frequency of in Vitro Fluconazole Resistance in a Select Population-A Brief Note.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36630418" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Vaginal Candida albicans: High Frequency of in Vitro Fluconazole Resistance in a Select Population-A Brief Note.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27687503" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Candida vulvovaginitis: A store with a buttery and a show window.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7795112" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Treatment options for vulvovaginal candidiasis, 1993.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7726267" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7726267" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36083109" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Ibrexafungerp: A new triterpenoid antifungal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35412529" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Ibrexafungerp for the treatment of vulvovaginal candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34467969" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34676663" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9500502" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy. Vaginal Infections and Prematurity Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33867561" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Vulvovaginal Candidosis (Excluding Mucocutaneous Candidosis): Guideline of the German (DGGG), Austrian (OEGGG) and Swiss (SGGG) Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry Number 015/072, September 2020).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26746458" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29510088" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Vaginal antimycotics and the risk for spontaneous abortions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30782643" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11687074" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Topical treatment for vaginal candidiasis (thrush) in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11687074" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Topical treatment for vaginal candidiasis (thrush) in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11687074" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Topical treatment for vaginal candidiasis (thrush) in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29896619" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Oral Fluconazole in Pregnancy and Risk of Stillbirth and Neonatal Death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8987954" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18400803" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Maternal use of fluconazole and risk of congenital malformations: A Danish population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18400803" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Maternal use of fluconazole and risk of congenital malformations: A Danish population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23984730" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Use of oral fluconazole during pregnancy and the risk of birth defects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10030772" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Pregnancy outcomes after maternal exposure to fluconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10417502" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Risk of malformations and other outcomes in children exposed to fluconazole in utero.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8039528" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9746382" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32434758" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26640069" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Fluconazole use and birth defects in the National Birth Defects Prevention Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16265639" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Prenatal exposure to fluconazole: An identifiable dysmorphic phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16265639" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prenatal exposure to fluconazole: An identifiable dysmorphic phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16265639" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Prenatal exposure to fluconazole: An identifiable dysmorphic phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11518893" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Treatment of complicated Candida vaginitis: Comparison of single and sequential doses of fluconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11518893" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Treatment of complicated Candida vaginitis: Comparison of single and sequential doses of fluconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34292794" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Risks for Recurrent Vulvovaginal Candidiasis Caused by Non-Albicans Candida Versus Candida Albicans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35968569" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Recurrent vulvovaginal candidiasis with Candida glabrata - a management conundrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30384449" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : An Update on the Roles of Non-albicansCandida Species in Vulvovaginitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31417505" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Microsatellite Typing and Antifungal Susceptibility of Candida glabrata Strains Isolated From Patients With Candida Vaginitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9145739" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Treatment of Torulopsis glabrata vaginitis: Retrospective review of boric acid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14634557" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Treatment of vaginitis caused by Candida glabrata: Use of topical boric acid and flucytosine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26083330" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Non-albicans Candida Vulvovaginitis: Treatment Experience at a Tertiary Care Vaginitis Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26083330" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Non-albicans Candida Vulvovaginitis: Treatment Experience at a Tertiary Care Vaginitis Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15970877" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19570754" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Therapeutic efficacy of voriconazole against a fluconazole-resistant Candida albicans isolate in a vaginal model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19570754" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Therapeutic efficacy of voriconazole against a fluconazole-resistant Candida albicans isolate in a vaginal model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36214529" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Outcomes and experiences of using oral voriconazole with or without concomitant topical agents to treat refractory vulvovaginal yeast infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11402233" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32400853" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Update on Candida krusei, a potential multidrug-resistant pathogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26164695" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Recurrent vulvovaginal candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29168557" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Probiotics for vulvovaginal candidiasis in non-pregnant women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24308540" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The effects of oral garlic on vaginal candida colony counts: a randomised placebo controlled double-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32107396" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Garlic alters the expression of putative virulence factor genes SIR2 and ECE1 in vulvovaginal C. albicans isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36141261" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Vapor-Phase of Essential Oils as a Promising Solution to Prevent Candida Vaginal Biofilms Caused by Antifungal Resistant Strains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37023426" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Comparison of tea tree oil 5%, tea tree oil 10%, and nystatin inhibition zones against vaginal Candida isolates in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17560449" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Vulvovaginal candidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33529414" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1607194" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11360070" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : The value of treating the male partner in vaginal candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3510660" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Co-treatment of the male partner in vaginal candidosis: A double-blind randomized control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3510660" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Co-treatment of the male partner in vaginal candidosis: A double-blind randomized control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3510660" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Co-treatment of the male partner in vaginal candidosis: A double-blind randomized control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11533352" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Transfer of drugs and other chemicals into human milk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11533352" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Transfer of drugs and other chemicals into human milk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26759844" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Fluconazole use during breastfeeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26759844" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Fluconazole use during breastfeeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26759844" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Fluconazole use during breastfeeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26759844" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Fluconazole use during breastfeeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26759844" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Fluconazole use during breastfeeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26759844" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Fluconazole use during breastfeeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/380743" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Vaginal microbial flora in normal young women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19558525" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Vaginal and endocervical microorganisms in symptomatic and asymptomatic non-pregnant females: Risk factors and rates of occurrence.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
